What is Adcentrx Therapeutics?
Founded in 2021 and based in San Diego, California, Adcentrx Therapeutics is a biotechnology company dedicated to accelerating the development of novel protein conjugate therapeutics. The company's primary focus lies in creating innovative treatments for cancer and other life-threatening conditions, positioning itself at the forefront of therapeutic innovation in the life sciences sector. This strategic financing will likely fuel its research and development pipeline and expand its operational capabilities.
How much funding has Adcentrx Therapeutics raised?
Adcentrx Therapeutics has raised a total of $101M across 2 funding rounds:
Other Financing Round
$50M
Series A
$51M
Other Financing Round (2021): $50M with participation from Zoo Capital and CBC Group
Series A (2023): $51M led by Eight Roads Ventures, Quan Capital, Partners Investment, F-Prime Capital, and Delta Capital
Key Investors in Adcentrx Therapeutics
Eight Roads Ventures
Eight Roads Ventures is an investment firm with a focus on real estate, venture, and growth businesses, likely bringing strategic guidance to Adcentrx Therapeutics' expansion.
Quan Capital
Quan Capital is a healthcare-focused global venture capital firm that invests in startups within the healthcare, pharmaceutical, and biotech sectors, offering deep industry expertise and a strong network.
F-Prime Capital
F-Prime Capital, established in 2002, invests in healthcare and technology companies, providing a team of experts to support Adcentrx Therapeutics' innovation and growth.
What's next for Adcentrx Therapeutics?
With a major strategic investment and a significant overall funding amount, Adcentrx Therapeutics is poised for accelerated growth and development. The capital infusion is expected to bolster its efforts in protein conjugate therapeutic research, potentially leading to faster clinical trials and market entry. This backing from prominent investors signals strong confidence in the company's technology and its potential to address unmet medical needs in oncology and beyond. The company's next steps will likely involve scaling its operations, expanding its research team, and advancing its lead therapeutic candidates through the development pipeline.
See full Adcentrx Therapeutics company page
